Susceptibility of Fosfomycin against Vancomycin Resistant Enterococci.
- Author:
Soon Duk PARK
1
;
Young UH
;
Gyu Yel HWANG
;
Kap Jun YOON
;
Hyo Youl KIM
Author Information
1. Department of Clinical Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Publication Type:Original Article
- Keywords:
Fosfomycin;
Vancomycin resistant enterococci (VRE);
Enterococcus faecalis;
Enterococcus faecium;
Enterococcus casseliflavus;
Enterococcus gallinarum
- MeSH:
Anti-Infective Agents;
Diffusion;
Enterococcus faecalis;
Enterococcus faecium;
Fosfomycin*;
Gangwon-do;
Incidence;
Korea;
Vancomycin*
- From:Korean Journal of Infectious Diseases
2001;33(3):181-185
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Vancomycin-resistant enterococci (VRE) were first recovered from clinical isolates in Korea in 1992, and the incidence has been steadily increasing. Alternatives to vancomycin are few because VRE are frequently resistant to commonly used antimicrobial agents. The present study was designed to assess the in-vitro activity of fosfomycin to clinical isolates of VRE. METHODS: For 199 VRE isolates from 1995 to 2000, and 91 enterococcal isolates that were consecutively isolated during the January of 2001 at Wonju Christian Hospital, fosfomycin (200 microgram) disk diffusion test was done by NCCLS method. The number of enterococcal isolates tested for fosfomycin were as follows:58 E. faecalis (42 vancomycin susceptible isolates, 16 vancomycin resistant isolates, and 1 vancomycin intermediate resistance isolate); 210 E. faecium (185 vancomycin resistant and 25 vancomycin susceptible isolates); 15 E. gallinarum, and 6 E. casseliflavus isolates. RESULTS: Among the VRE isolates, the resistance rates of fosfomycin according to enterococcal species were 6.3% in E. faecalis, 4.9% in E. faecium, 0% in E. casseliflavus, and 16.7% in E. gallinarum. CONCLUSION: Fosfomycin could be a potentially useful drug for the treatment of infections caused by VRE.
